Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

A P Lea1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Virosomal hepatitis A vaccine, using influenza virosomes as an adjuvant, demonstrates high immunogenicity and protection against hepatitis A infection. Preliminary data suggest long-lasting immunity and good local tolerability in children and adults.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Topical eflornithine.

American journal of clinical dermatology·2001
Same author

Telithromycin.

Drugs·2001
Same author

Bendamustine.

Drugs·2001
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Vaccinology
  • Immunology
  • Virology

Background:

  • Hepatitis A remains a significant public health concern, necessitating effective vaccination strategies.
  • Virosomal technology offers a novel approach to vaccine adjuvantation, potentially enhancing immune responses.
  • The development of safe and immunogenic hepatitis A vaccines is crucial for disease prevention.

Purpose of the Study:

  • To evaluate the immunogenicity and protective efficacy of a virosomal hepatitis A vaccine.
  • To assess the duration of antibody response and local tolerability of the vaccine.
  • To compare the virosomal vaccine's performance with existing hepatitis A vaccines.

Main Methods:

  • Noncomparative and comparative studies involving adults and children.

Related Experiment Videos

  • Administration of formalin-inactivated hepatitis A antigen adsorbed onto immunopotentiating reconstituted influenza virosomes (IRIVs).
  • Measurement of anti-hepatitis A virus (anti-HAV) antibody titres and seroconversion rates.
  • Assessment of protective efficacy through clinical trials and analysis of adverse effects.

    • Main Results:

    • High immunogenicity observed, with rapid seroconversion in most vaccinees.
    • Booster doses significantly increased anti-HAV antibody titres.
    • Estimated protection duration of 8 to 12.5 years, with potential for longer-lasting immunity.
    • Preliminary efficacy of 95% in a randomized trial; favorable local tolerability compared to aluminum hydroxide-adsorbed vaccines.

    Conclusions:

    • The virosomal hepatitis A vaccine (strain RG-SB) is highly immunogenic and demonstrates promising protective efficacy.
    • The vaccine appears to offer long-lasting protection with a favorable safety profile.
    • Further evaluation of duration of protection and cost-effectiveness is needed for its definitive role in hepatitis A prevention.